Additional File

Performance Evaluation of In Vitro Diagnostic Kits for Hepatitis B Virus Infection Using the Regional Reference Panel of Japan

Haruka Momose, Asako Murayama, Norie Yamada, Keiji Matsubayashi,

Sahoko Matsuoka, Emi Ikebe, Madoka Kuramitsu, Masamichi Muramatsu,

Takanobu Kato, Isao Hamaguchi.

| Kits | Manufacture | Method | Target | Dynamic range (log IU/mL) |
|------------------|-------------------|--------|--------|------------------------------|
| ART HBV | Abbott Japan | qPCR | HBs | 1.00–9.00 |
| Alinity HBV | | | | |
| CAP/CTM HBV v2.0 | Poobo Diagnostico | qPCR | preC/C | 1.30–8.23 |
| Cobas HBV | | | | 1.00–9.00 |
| Aptima HBV | Hologic | ТМА | HBs | 1.00–9.00 |

Table S1. HBV DNA kits evaluated in this study.

qPCR; quantitative PCR, TMA; Transcription Mediated Amplification, HBs; hepatitis B surface,

preC/C; hepatitis B precore/core region.

| HBsAg kits | | Manufacture | Method | Cut off (IU/mL) |
|--------------|------------------|--------------------|--------|-----------------|
| Quantitative | Lumipulse | | | 0.005 |
| Presto | | FUJIREBIO | | 0.005 |
| | HISCL | Sysmex | CLEIA | 0.03 |
| | CL AIA | Tosoh | CLEIA | 0.03 |
| | Accuraseed | FUJIFILM Wako | CLEIA | 0.05 |
| | Architect | Abbott Japan | CLIA | 0.05 |
| | Alinity | Abboli Japan | | |
| | Elecsys quant II | Roche Diagnostics | ECLIA | 0.05 |
| Qualitative | ST AIA | Tosoh | FEIA | 0.05 |
| | STACIA | LSI Medience | CLEIA | N/A |
| | Centaur II | Siemens | CLIA | N/A |
| | Elecsys II | Roche Diagnostics | ECLIA | N/A |
| LFA | Determine | Abbott Diagnostics | LFA | N/A |
| | Determine2 | Medical | | |

Table S2. HBsAg kits evaluated in this study.

CLIA; Chemiluminescent immunoassay, CLEIA; Chemiluminescent enzyme immunoassay, ECLIA; Electrochemiluminescence immunoassay, FEIA; Fluorescence enzyme immunoassay, LFA; Lateral flow assay, N/A; not applicable.



Figure S1. Deviation of HBV DNA titers quantified by CAP/CTM HBV v2.0.

Deviations of HBV DNA titers by CAP/CTM HBV v2.0 from Alinity HBV (A) and Cobas HBV (B) were analyzed by the Bland–Altman method. Specimens with significantly low titers in CAP/CTM HBV v2.0 are indicated by colored circles. Red; GTA, blue; GTB, green; GTC.

Figure S2.



Figure S2. Genotype-dependent differences in HBsAg titers compared to Lumipulse.

Correlations of HBsAg titers of Alinity, CL AIA, Accuraseed, HISCL, and Elecsys quant II were analyzed against Lumipulse. Data and linear regression lines are shown in dots and lines, respectively. Dashed lines indicate a slope of 1.0.



Figure S3. Genotype-dependent differences in HBsAg titers compared to Alinity.

Correlations of HBsAg titers of Lumipulse, CL AIA, Accuraseed, HISCL, and Elecsys quant II were analyzed against Alinity. Data and linear regression lines are shown in dots and lines, respectively. Dashed lines indicate a slope of 1.0.



Figure S4. Genotype-dependent differences in HBsAg titers compared to Elecsys quant II.

Correlations of HBsAg titers of Alinity, CL AIA, Accuraseed, HISCL, and Lumipulse were analyzed against Elecsys quant II. Data and linear regression lines are shown in dots and lines, respectively. Dashed lines indicate a slope of 1.0.